Patents by Inventor Cedric CALLENS

Cedric CALLENS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
    Patent number: 11608330
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: March 21, 2023
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Caroline Springer, Richard Marais, Dan Niculescu-Duvaz, Leo Leung, Deborah Smithen, Cedric Callens, Haoran Tang
  • Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer
    Publication number: 20220372028
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 24, 2022
    Inventors: Caroline SPRINGER, Richard MARAIS, Dan NICULESCU-DUVAZ, Leo LEUNG, Deborah SMITHEN, Cedric CALLENS, Haoran TANG
  • Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
    Patent number: 10995088
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: May 4, 2021
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Caroline Springer, Richard Marais, Dan Niculescu-Duvaz, Leo Leung, Deborah Smithen, Cedric Callens, Haoran Tang
  • Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer
    Publication number: 20210040078
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Application
    Filed: June 22, 2020
    Publication date: February 11, 2021
    Inventors: Caroline SPRINGER, Richard MARAIS, Dan NICULESCU-DUVAZ, Leo LEUNG, Deborah SMITHEN, Cedric CALLENS, Haoran TANG
  • Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
    Patent number: 10807974
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 20, 2020
    Assignee: The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Caroline Springer, Richard Marais, Dan Niculescu-Duvaz, Leo Leung, Deborah Smithen, Cedric Callens, Haoran Tang
  • Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer
    Publication number: 20190152966
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 23, 2019
    Applicant: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Caroline SPRINGER, Richard MARAIS, Dan NICULES-CU-DUVAZ, Leo LEUNG, Deborah SMITHEN, Cedric CALLENS, Haoran TANG